MAIA Biotechnology (MAIA) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MAIA Biotechnology (MAIA) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 36.5% versus a loss of 57.5%. Oncolytics Biotech is the larger company by market cap ($71.4 million vs $71.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | ONCY |
|---|---|---|
| Share price | $1.15 | $0.5444 |
| Market cap | $71.00M | $71.38M |
| 1-day change | -2.54% | -8.63% |
| YTD return | -24.84% | -37.43% |
| 1-year return | -36.46% | -57.47% |
| 5-year return | — | -75.48% |
| Forward P/E | 1.04 | — |
| EPS (TTM) | $-0.62 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.19 | $1.32 |
| 52-week low | $0.87 | $0.54 |
| Distance from 52-week high | -63.95% | -58.76% |
| Analyst consensus | none | buy |
| Avg. price target upside | +943.48% | +662.31% |
| Average volume | 527.89K | 1.08M |
| Shares outstanding | 61.74M | 131.12M |
| Employees | 13 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MAIA has outperformed ONCY by 21.0 percentage points over the past year.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
MAIA vs ONCY FAQ
Which is bigger, MAIA Biotechnology or Oncolytics Biotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $71.38M compared with $71.00M for MAIA Biotechnology (MAIA).
Which stock has performed better over the past year, MAIA or ONCY?
MAIA returned -36.46% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are MAIA Biotechnology and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.